OGX-427: Final Phase I data

Final data from a Phase I trial in 48 patients who failed up to 6 prior chemotherapy regimens showed that OGX-427 was well tolerated as a single agent and in combination with Taxotere docetaxel. OGX-427 as monotherapy reduced measurable disease by >=20% in 3 of 17 evaluable patients, reduced levels of CA-125 by >=25% in 2 of 4 evaluable ovarian cancer patients, and reduced prostate-specific antigen (PSA) by >=30% in 3 of 15 evaluable prostate cancer patients. OGX-427 plus Taxotere reduced measurable disease by >=20% in 5 of 10 evaluable patients and reduced PSA by >=30% in 5 of 9 evaluable prostate cancer patients. The trial enrolled breast, ovarian, prostate and non-small cell lung cancer (NSCLC) patients who received 200, 400, 600, 800 or 1,000 mg weekly OGX-427. The MTD was not reached. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...